Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GTXI $0.70 0.1128 +19.21%
IMGN $9.46 1.1600 +13.98%
ARGS $9.00 0.8500 +10.43%
TLOG $4.13 0.2600 +6.72%
ARIA $5.80 0.3600 +6.62%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.20 -0.0500 -20.00%
CPXX $1.99 -0.3986 -16.69%
MNKD $5.36 -0.3300 -5.80%
CERU $4.49 -0.2300 -4.87%
RDHL $9.80 -0.4500 -4.39%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Early Breast Cancer Study Results Said Reassuring

(San Francisco Chronicle) Mar 12, 2011 - Treating early breast cancers with radiation and drugs, in addition to removing part of the breast itself, significantly decreases the risk of developing a more invasive form of cancer 15 years later, according to a Stanford study released Friday.
read article 

Second-Line TKIs Offer Expanded Treatment Options for Newly Diagnosed Patients with CML

(NCCN) Mar 11, 2011 - Second generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of chronic myelogenous leukemia (CML) offer newly diagnosed patients an expanded range of treatment options, according to Susan O’Brien, MD, of The University of Texas MD Anderson Cancer Center and chair of the NCCN Guidelines™ for CML.
read press release 

BTG Drug Developed By Glaxo And Tolerx Misses Study End Point

(Morningstar/Dow Jones Newswires) Mar 11, 2011 - GlaxoSmithKline PLC and U.S. partner Tolerx, Inc. said Friday their experimental drug otelixizumab failed to achieve its target in a late-stage clinical trial for Type 1 diabetes.
read article 

AstraZeneca to Pay $68.5 Million to U.S. States Over Seroquel Marketing

(Bloomberg) Mar 10, 2011 - AstraZeneca Plc agreed to pay $68.5 million to 37 U.S. states and the District of Columbia to resolve allegations that the company deceptively marketed its anti-psychotic drug Seroquel.
read article 

Bapineuzumab Might Tackle Alzheimer’s Protein Early On

(WSJ Health Blog) Mar 10, 2011 - Many scientists believe that Alzheimer’s disease is caused in part by a sticky substance called amyloid that clumps in the brain to cause plaques.
read article (paid subscription required) 

Hospitals Try Cooking Up Better Food for Patients

(Bloomberg Businessweek) Mar 10, 2011 - If there is a five-star kitchen in the world of hospital food, it might be at Memorial Sloan-Kettering Cancer Center, where top restaurant veteran chef Pnina Peled has attracted attention for the creative dishes she whips up for young cancer patients.
read article 

Rethinking Societal Attitudes About People Who Get Cancer

(The Huffington Post) Mar 11, 2011 - In her 1978 book, "Illness as Metaphor," Susan Sontag argued that societal myths and metaphors surrounding disease can kill. How? By instilling shame and guilt in the sick.
read article 

131 Medical Societies Call for Permanent Payment Fix

(ASCO in Action) Mar 11, 2011 - On March 10, ASCO and 130 state and medical specialty societies sent a letter to both the U.S. House and Senate calling for a permanent solution this year to the broken Medicare physician payment formula.
read article 

Senator Calls for Drug Shortage Investigation

(ASCO in Action) Mar 11, 2011 - On March 3rd, Senator Richard Blumenthal (D-CT) requested that the Government Accountability Office (GAO) “immediately launch an investigation of a pressing problem that threatens Americans’ adequate access to prescription drugs.”
read article 

Cancer Patient: Approval For New Drugs Takes Too Long

( Mar 10, 2011 - How long is too long to make cancer patients wait for promising new drugs? One local couple is frustrated with the Food and Drug Administration's approval process and is demanding changes.
read article 

Post-Transplant Lymphoproliferative Disorder Section Integrated into Updated NCCN Guidelines for NHL

(Morningstar) Mar 11, 2011 - A new Guideline detailing diagnosis, workup, and treatment options for Post-Transplant Lymphoproliferative Disorder (PTLD), as well as stronger recommendations for therapies in follicular lymphoma, topped the list of highlights in a presentation of the updated NCCN Guidelines™ for Non-Hodgkin’s Lymphomas (NHL).
read article 

UCLA Scientists Create New Cell Lines From Ocular Melanoma Patients

(UCLA) Mar 10, 2011 - Researchers at UCLA's Jules Stein Eye Institute have created new tumor cell lines from fine-needle biopsies of ocular melanoma patients who had undergone treatment but died when their cancer spread aggressively.
read press release 

No Signs Dietary Supplements Prevent Bladder Cancer

(Reuters) Mar 10, 2011 - Popping vitamins, minerals or anti-inflammatory substances like garlic or fish oil doesn't appear to stave off bladder cancer, a large U.S. study shows.
read article 

Considering Hormone Replacement Therapy?

(Los Angeles Times) Mar 9, 2011 - Recent research shows that women who start the most common type of hormone therapy — estrogen plus progestin — soon after menopause have a significantly higher risk of breast cancer than those who take the hormones later or not at all.
read article (free registration required) 

Blood Test May Spot Inherited Ovarian Cancer

(WebMD) Mar 9, 2011 - Nearly one in four ovarian cancers are inherited, say researchers who are developing a gene-based blood test to identify women with these hereditary cancers.
read article 

Dendreon Gets FDA Approval To Expand Provenge Production

(Morningstar/Dow Jones Newswires) Mar 10, 2011 - Dendreon Corp. received U.S. Food and Drug Administration approval to quadruple the production capacity of supply- constrained prostate-cancer drug Provenge at its New Jersey manufacturing facility.
read article 

Lack of Appropriate Evidence Forces NICE to Turn Down Ovarian Cancer Drug in Draft Guidance

(NICE) Mar 11, 2011 - In draft guidance issued today NICE's expert independent advisory committee has not recommended trabectedin (Yondelis, PharmaMar) in combination with pegylated liposomal doxorubicin (PLDH) as a treatment for ovarian cancer because of concerns over how well it works compared with the most commonly-used treatments.
read press release 

Sanofi-Aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer

(Regeneron) Mar 10, 2011 - Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).
read press release 

BU Pediatrician Named Editor of Leading Medical Journal

(Boston Globe) Mar 9, 2011 - A professor of pediatrics and community health sciences at Boston University School of Medicine has been named the new editor of the Journal of the American Medical Association.
read article (free registration required) 

Roche's Lucentis Helps Diabetics' Vision

(Reuters) Mar 10, 2011 - Diabetics suffering from a complication that can cause blindness can see better when treated with Roche's eye drug Lucentis, giving the medicine a slight lift ahead of another keenly awaited trial.
read article 

ARYx Therapeutics To Wind Down Operations After FDA Delay

(Morningstar/Dow Jones Newswires) Mar 9, 2011 - ARYx Therapeutics Inc. said it will immediately begin to wind down the company's operations after the U.S. Food and Drug Administration further delayed guidance for the biopharmaceutical firm's Phase 3 product candidate.
read article 

What Standards Will Apply To Federal Drug ‘Unsales’ Force?

(Forbes On the Docket Blog) Mar 9, 2011 - Proponents of health care “reform” have invested an enormous amount of time and effort proclaiming how pharmaceutical company sales representatives (colloquially known as “detailers”) and their visits to medical professionals increase the cost of patient treatments and, in turn, health care in general.
read article 

The Next Physician Access Problem: Medicare

(Forbes Health Blog) Mar 9, 2011 – Sadly, Medicare now creates incentives for doctors to select the most expensive drugs when treating patients.
read article 

FDA Approves New Drug to Treat Lupus

(Washington Post) Mar 9, 2011 - The Food and Drug Administration approved the first treatment designed for lupus in half a century Wednesday, a decision that stands to generate billions of dollars over several years for Human Genome Sciences of Rockville and its development partner, GlaxoSmithKline.
read article (free registration required) 

Eating You Alive: Environmental Cancer

(Forbes Green Conversations Blog) Mar 9, 2011 - Most humans, and probably most vertebrates in general, have tumor cells in their bodies, if not now then at some point in their lives. Yet, according to the U.S. Department of Health and Human Services “in the U.S., only 41% (of the human population) ever get cancer.”
read article